JP2010513430A5 - - Google Patents

Download PDF

Info

Publication number
JP2010513430A5
JP2010513430A5 JP2009542179A JP2009542179A JP2010513430A5 JP 2010513430 A5 JP2010513430 A5 JP 2010513430A5 JP 2009542179 A JP2009542179 A JP 2009542179A JP 2009542179 A JP2009542179 A JP 2009542179A JP 2010513430 A5 JP2010513430 A5 JP 2010513430A5
Authority
JP
Japan
Prior art keywords
kit
pharmaceutically acceptable
disease
solvate
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009542179A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010513430A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2007/004408 external-priority patent/WO2008074975A1/en
Publication of JP2010513430A publication Critical patent/JP2010513430A/ja
Publication of JP2010513430A5 publication Critical patent/JP2010513430A5/ja
Pending legal-status Critical Current

Links

JP2009542179A 2006-12-18 2007-11-16 炎症障害の治療において使用するための新たな併用 Pending JP2010513430A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87537706P 2006-12-18 2006-12-18
US74307P 2007-10-29 2007-10-29
PCT/GB2007/004408 WO2008074975A1 (en) 2006-12-18 2007-11-16 New combination for use in the treatment of inflammatory disorders

Publications (2)

Publication Number Publication Date
JP2010513430A JP2010513430A (ja) 2010-04-30
JP2010513430A5 true JP2010513430A5 (cg-RX-API-DMAC7.html) 2011-01-06

Family

ID=39135213

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009542179A Pending JP2010513430A (ja) 2006-12-18 2007-11-16 炎症障害の治療において使用するための新たな併用

Country Status (20)

Country Link
US (1) US20100063070A1 (cg-RX-API-DMAC7.html)
EP (1) EP2120919B1 (cg-RX-API-DMAC7.html)
JP (1) JP2010513430A (cg-RX-API-DMAC7.html)
KR (1) KR20090106526A (cg-RX-API-DMAC7.html)
CN (1) CN101610765A (cg-RX-API-DMAC7.html)
AU (1) AU2007336118A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0720358A2 (cg-RX-API-DMAC7.html)
CA (1) CA2672976A1 (cg-RX-API-DMAC7.html)
CY (1) CY1113636T1 (cg-RX-API-DMAC7.html)
DK (1) DK2120919T3 (cg-RX-API-DMAC7.html)
EA (1) EA200900815A1 (cg-RX-API-DMAC7.html)
ES (1) ES2394984T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20120923T1 (cg-RX-API-DMAC7.html)
IL (1) IL199214A (cg-RX-API-DMAC7.html)
MX (1) MX2009006507A (cg-RX-API-DMAC7.html)
NO (1) NO20092134L (cg-RX-API-DMAC7.html)
NZ (1) NZ577467A (cg-RX-API-DMAC7.html)
PT (1) PT2120919E (cg-RX-API-DMAC7.html)
SI (1) SI2120919T1 (cg-RX-API-DMAC7.html)
WO (1) WO2008074975A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32711A (es) 2009-06-16 2011-01-31 Cardoz Ab Nueva forma cristalina de pemirolast
CA2780382A1 (en) * 2009-11-13 2011-05-19 Cardoz Ab Pemirolast for the treatment of systemic low grade inflammation
CN102302780B (zh) * 2011-09-01 2013-05-01 刘树芹 一种治疗支气管哮喘的药物组合物
CN102389418A (zh) * 2011-09-01 2012-03-28 刘树芹 一种含扎鲁司特和他汀类药物的药物组合物
CN102274515B (zh) * 2011-09-01 2013-04-24 刘树芹 一种含孟鲁司特和他汀类药物的药物组合物
CA3087344A1 (en) 2018-01-05 2019-07-11 Platelet Biogenesis, Inc. Compositions and methods for producing megakaryocytes
JP2021529770A (ja) * 2018-06-29 2021-11-04 プレートレット バイオジェネシス, インコーポレイテッド 薬物送達のための組成物およびその使用方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4122274A (en) * 1977-05-25 1978-10-24 Bristol-Myers Company 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones
JP2504788B2 (ja) * 1987-11-10 1996-06-05 東京田辺製薬株式会社 9−メチル−3−(1H−テトラゾ―ル−5−イル)−4H−ピリド[1,2−a]ピリミジン−4−オンカリウム塩の水性製剤
WO1995032714A1 (en) * 1994-05-31 1995-12-07 Tokyo Tanabe Company Limited Arteriosclerosis depressant
WO1997045105A1 (en) * 1996-05-24 1997-12-04 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing diseases of body passageways
US7115278B2 (en) * 1998-04-08 2006-10-03 Theoharis C Theoharides Proteoglycan compositions for the treatment of cardiovascular inflammatory diseases
US6232297B1 (en) * 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US20030235595A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
JP2003509478A (ja) * 1999-09-21 2003-03-11 エモリー・ユニバーシティ 血小板関連障害を処置する方法および組成物
US6379684B1 (en) * 2001-05-02 2002-04-30 Alphamed Pharaceutical Corp. Cosmetic compositions containing cromolyn compounds for revitalizing the skin
ITMI20011764A1 (it) * 2001-08-10 2003-02-10 Dinamite Dipharma Spa Metodo per l'ottenimento del pemirolast ad elevata purezza
JPWO2004002530A1 (ja) * 2002-06-26 2005-10-27 小野薬品工業株式会社 慢性疾患治療剤
JP4607436B2 (ja) * 2002-08-02 2011-01-05 第一三共株式会社 HMG−CoAリダクターゼ阻害剤を含有する医薬組成物
JP4588986B2 (ja) * 2002-08-20 2010-12-01 テルモ株式会社 体内埋込医療器具
EP1553075B1 (en) * 2002-10-03 2013-08-14 Ono Pharmaceutical Co., Ltd. Lpa receptor antagonists
AU2004305154A1 (en) * 2003-12-23 2005-07-07 Medicure International Inc. Combination therapies employing a composition comprising a HMG CoA reductase inhibitor and a vitamin B6 related compound
US8277831B2 (en) * 2004-02-17 2012-10-02 Advanced Technologies And Regenerative Medicine, Llc. Drug-enhanced adhesion prevention
US20060084695A1 (en) * 2004-04-29 2006-04-20 John Griffin Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US7803838B2 (en) * 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
CA2593545A1 (en) * 2005-01-06 2006-07-13 Merck & Co., Inc. Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
US7202325B2 (en) * 2005-01-14 2007-04-10 Advanced Cardiovascular Systems, Inc. Poly(hydroxyalkanoate-co-ester amides) and agents for use with medical articles
NZ560386A (en) * 2005-01-31 2009-12-24 Mylan Lab Inc Pharmaceutical composition comprising hydroxylated nebivolol
US20070225301A1 (en) * 2006-02-13 2007-09-27 Astion Inflammation Aps Treatment of acne and other diseases
US8445437B2 (en) * 2006-07-27 2013-05-21 The Brigham And Women's Hospital, Inc. Treatment and prevention of cardiovascular disease using mast cell stabilizers
CA2677493A1 (en) * 2007-02-05 2008-08-14 Xenon Pharmaceuticals Inc. Pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditions

Similar Documents

Publication Publication Date Title
Aggarwal et al. Cardiovascular safety of potential drugs for the treatment of coronavirus disease 2019
JP2022180461A5 (cg-RX-API-DMAC7.html)
Shen et al. Effects of Lipo-Prostaglandin E1on Pulmonary Hemodynamics and Clinical Outcomes in Patients With Pulmonary Arterial Hypertension
EP1961744A4 (en) CONNECTION WITH BASIC GROUPS AND ITS USE
JP2019048843A5 (cg-RX-API-DMAC7.html)
HRP20120923T1 (hr) Nova kombinacija za upotrebu u lijeäśenju inflamatornih poremeä†aja
HRP20170624T1 (hr) Derivat piridina i pirazina za liječenje kronične opstrukcijske plućne bolesti
JP2016172781A5 (cg-RX-API-DMAC7.html)
CN110036005A (zh) 酰胺衍生物及其在药物中的应用
JP2016510326A5 (cg-RX-API-DMAC7.html)
JP2020193206A5 (cg-RX-API-DMAC7.html)
JP2014511891A5 (cg-RX-API-DMAC7.html)
JP2013537903A (ja) カラノライド、その誘導体及び類似体についての医薬組成物並びにそれを製造するための方法
JP2015505565A5 (cg-RX-API-DMAC7.html)
FI3250182T3 (fi) Dispergoituvia koostumuksia
JP2023090869A5 (cg-RX-API-DMAC7.html)
AU2014249168A1 (en) Methods of inhibiting leukotriene A4 hydrolase
JP2020528888A5 (cg-RX-API-DMAC7.html)
PH12022550539A1 (en) Therapeutic fusion proteins
JP2017529830A5 (cg-RX-API-DMAC7.html)
JP2019535760A5 (ja) ガボキサドールを用いた注意欠陥多動性障害(adhd)の治療方法
JP2015120685A5 (cg-RX-API-DMAC7.html)
JP2017533220A5 (cg-RX-API-DMAC7.html)
WO2017182873A3 (en) Peptide-oligourea foldamer compounds and methods of their use
JP2021073257A5 (cg-RX-API-DMAC7.html)